laser and cryotherapy are required for local control of disease. It is known that consolidative therapy can induce retinal pigment epithelium (RPE) hyperplasia and gliosis. Herein we report extensive RPE hyperplasia and gliosis during laser therapy for a focal scar recurrence, which presented as a progressive retinal opacification mimicking active retinoblastoma. Method: This is a retrospective case review. Results: A 2-month-old premature male was diagnosed with sporadic bilateral retinoblastoma (International Intraocular Retino- 
Novel Insights
• A progressively advancing opaque white lesion in an eye undergoing treatment for retinoblastoma may be secondary to retinal pigment hyperplasia and glial proliferation.
• Optical coherence tomography technology can be useful to detect areas of true tumor activity in areas of recurrence.
Introduction
The emergence of new treatment modalities for retinoblastoma has improved globe salvage rates while also reducing systemic side effects; however, intraocular recurrences of this cancer are common, and, thus, it remains critically important for the ocular oncologist to monitor the eye closely for disease recurrence [1] . This is especially true in the first 6 months after intravenous or intra-arterial chemotherapy when recurrences from scars or new tumor formation in predisposed patients are more likely [2] . The treatment of these recurrences is often even more challenging than the initial management.
Retinal pigment epithelium (RPE) hyperplasia is a rare but known ocular side effect of therapy in retinoblastoma patients. It can occur as a result of RPE toxicity from intra-arterial and/or intravitreal chemotherapy, as well as from local laser therapy [3] [4] [5] [6] . Indeed, laser photocoagulation, a common method used for the consolidative treatment of retinoblastoma, has been proven to induce RPE hyperplasia in and around the laser site on the retina using a mouse model [7, 8] . However, most pigmentation patterns of RPE hyperplasia and/or hypertrophy are in contrast to retinoblastoma [3] ; RPE changes often appear flat and darkly pigmented, occasionally presenting with a subretinal cleft, and do not tend to show significant or rapid growth, thus differentiating RPE hyperplasia from intraocular tumors [9] . Rarely, however, RPE hyperplasia may mimic an intraocular tumor [3, 10] . Herein, we present an unusual case of atypical RPE hyperplasia occurring during aggressive laser treatment for a recalcitrant retinoblastoma scar recurrence. We detail the clinical and pathological features and the management utilized during treatment.
Case Presentation
A 2-month-old premature male born at 31 weeks was diagnosed with sporadic bilateral retinoblastoma (International Intraocular Retinoblastoma Classification [IIRC] group B in the right eye and IIRC group A in the left eye [11] ). The patient was treated initially with 3 cycles of 3-drug systemic chemotherapy per the previously published protocol at Children's Hospital Los Angeles [12] . Laser consolidation was initiated after the initial cycle, and the patient was followed at 4-weekly intervals.
Following therapy, the patient had stable disease until a recurrence was noted in the group B eye during examination under anesthesia at approximately 9 months of age (4 months after the last cycle of chemotherapy). Repeat laser consolidation was used as treatment for the recurrence with initial resolution of the tumor (Fig. 1a) ; however, at 22 months of age, the patient was observed to have an additional tumor recurrence from the same chorioreti- 118 nal scar, prompting continued laser consolidation every 3-4 weeks (Fig. 1b) . Although the recurrence appeared to be responding to laser therapy, there was worsening subretinal fluid and eventually complete optic nerve obscuration secondary to the tumor and fibrotic scar. Moreover, the retina adjacent to the nodular recurrence exhibited increasing retinal whitening and opacification (Fig. 1c) . Hand-held optical coherence tomography (OCT) demonstrated a nodular, homogenous mass overlying the optic nerve consistent with active retinoblastoma (Fig. 2f ) along with associated inner retinal thickening and obliteration of the inner retinal layers (Fig. 2e) . On funduscopic examination, an extensive area of the retina also appeared opaque and thickened. There were no vascular changes or hemorrhages, and fluorescein angiography was unrevealing with only mild staining in the area of whitening (Fig. 1d) . After 8 weeks and 3 subsequent sessions of repeat laser consolidation, the nodular recurrence was responding, but the thickening and opacification of the retina had increased in size both clinically (Fig. 1e) and on OCT evaluation. Given the clinical findings, there was a concern for retinal infiltration of recurrent tumor. Thus, the right eye was enucleated after a prolonged treatment course including systemic chemotherapy and 17 sessions of laser consolidation for tumor recurrence. Histopathological evaluation of the enucleated eye revealed macroscopic and microscopic correlation with funduscopic and imaging findings (Fig. 2) . There was a poorly differentiated retinoblastoma with intraretinal growth and with an active focal and superficial recurrence over the optic nerve associated with extensive regression and treatment effect (Fig. 2) . The eye demonstrated extensive posttherapy effects with large chorioretinal scars with associated RPE proliferation and gliosis involving the optic nerve head and adjacent posterior retina (Fig. 2, 3) . Immunohistochemistry showed that the active tumor was synaptophysin positive but negative for glial fibrillary acidic protein and both S100 protein and pancytokeratin. The bulk of the opaque white retinal mass was formed predominantly by RPE proliferation (pancytokeratin and S100 protein positive), fibrosis from the sclera, and glial proliferation (glial fibrillary acidic protein positive and S100 focally positive) (Fig. 4) . Both the optic nerve margin and postlaminar optic nerve were negative for tumor. Thus, although clinically the patient appeared to have a large recurrent infiltrative retinoblastoma in the region not responding to local therapy, there was only a small nodular and infiltrative recurrence, and the majority of the tumor mass was actually formed by an atypical presentation of exuberant RPE hypertrophy and glial proliferation.
Discussion
Retinal pigment epithelial hyperplasia with gliosis can rarely manifest as a retinoblastoma tumor recurrence, particularly in patients receiving multiple rounds of laser consolidation therapy. Although RPE hyperplasia, hypertrophy, and proliferation following laser therapy and chemotherapy in retinoblastoma patients have been documented, this case report demonstrates that, associated with glial proliferation, RPE hyperplasia can present as a progressive opaque white growth, thus mimicking the clinical presentation of active retinoblastoma, both on clinical exam and OCT imaging [3] [4] [5] [6] . The knowledge of the phenomenon is especially important in patients with increasing retinal whitening after having received multiple rounds of laser consolidation therapy, which is known to induce RPE and glial proliferation. Another phenomenon that clinicians should consider in this setting is proliferative vitreoretinopathy, which has been reported to cause progressive whitening and vitreoretinal changes in retinoblastoma eyes, including tractional and rhegmatogenous detachment [13] . While rare, RPE hyperplasia can thus present a diagnostic dilemma for the treating ocular oncologist. Nonetheless, in the setting of retinoblastoma, the presence of any progressive thickening or whitening of the retina with documented increase in size must be considered active disease until proven otherwise. 
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